As Actos Bladder Cancer Lawsuits Continue to Be Filed in the U.S., FDA Approves Generic Version
As Actos bladder cancer lawsuits continue to mount, Consumer Reports flagged the use of this popular type 2 diabetes medication as "''one bargain' to avoid" in a public health alert released on August 21, 2012. The announcement was prompted by the U.S. Food and Drug Administration (“FDA”)’s approval of pioglitazone, a generic form of the drug, on August 17.
This decision, which has already started to raise questions in the medical community, is unusual given the recent wave of studies that have found a link between the long-term use of Actos and bladder cancer, heart failure, bone fractures, and liver disease.
The generic version of Actos, which will be sold at a cheaper price than the name brand, was approved to be marketed in 15 milligram, 30 mg and 45 mg strengths.
You might be wondering why the FDA didn’t instead pull Actos from shelves given its dangers, rather than allow a cheaper version of it to be sold. Last summer, France and Germany recalled Actos when they learned of its frightening connection to bladder cancer.
If you developed bladder cancer after taking Actos for a long period of time, call the attorneys at Bernstein Liebhard LLP, who are investigating potential Actos bladder cancer lawsuits, at (877) 779-1414. Visit their website at Actos Lawsuit | Actos Bladder Cancer.